Tadalafil and the recurrence of acute urinary retentio
Phase 2
- Conditions
- Urological and Genital Diseases
- Registration Number
- PACTR202305669258195
- Lead Sponsor
- oghmari Ahmed
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 48
Inclusion Criteria
The study enrolled consenting male patients
Aged more than 45 years
Presenting acute urinary retention (AUR) (first episode) secondary to benign prostatic hyperplasia (BPH)
Not presenting personal history of AUR, prostate cancer, prostatectomy, tumorous duct obstruction, lower urinary tract infection, lower urinary tract surgery, AUR after surgery
With no simultaneous use of drugs having interactions with Tadalafil or Silodosine
Exclusion Criteria
Patients who did not complete the follow-up
Patients in whom a significant prostatic protrusion index was discovered during the study
Patients in whom a bladder lithiasis, or bladder diverticulum were discovered
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method